GlassScriptPhysician profile
Jaime G Ackerman
NPI 1013992544
$83,917.32
in general payments reported to CMS, 2019-2025
33 companies · $44K in 2025
The $44K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,396 · 2022: $4,972 · 2023: $3,732 · 2024: $26K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $14K · Consulting Fee: $14K · Food and Beverage: $9,426 · Education: $74.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,463.75 |
| Travel and Lodging | $14,330.37 |
| Consulting Fee | $14,254.49 |
| Food and Beverage | $9,426.04 |
| Education | $74.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $29,058.39 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26,689.33 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Phathom Pharmaceuticals, INC. | $20,580.46 | 2024-2025 | Voquezna |
| Abbvie INC. | $2,584.26 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $853.56 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $530.34 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $433.68 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $390.84 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $379.87 | 2024-2025 | Omvoh |
| Celgene Corporation | $344.51 | 2021-2024 | Zeposia |
| Pfizer INC. | $279.94 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $249.34 | 2022-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $232.03 | 2022-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $226.36 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $160.81 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $123.76 | 2021-2023 | Zinplava, Dificid |
| Madrigal Pharmaceuticals | $105.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $97.59 | 2021-2023 | Qsymia |
| Redhill Biopharma INC. | $85.86 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Daiichi Sankyo INC. | $77.86 | 2021-2023 | Injectafer |
| Enterra Medical, INC. | $65.01 | 2025 | |
| Aimmune Therapeutics, INC. | $64.13 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $63.60 | 2023-2024 | Yuflyma, Zymfentra |
| Organon LLC | $63.17 | 2024-2025 | Hadlima, Renflexis |
| Novo Nordisk INC | $28.65 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $28.34 | 2025 | Iqirvo |
| Amgen INC. | $23.69 | 2023 | Amjevita, Avsola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.69 | 2023 | |
| Evoke Pharma, INC. | $18.26 | 2024 | |
| Merit Medical Systems INC | $15.43 | 2025 | Esophyx, Endomaxx Stent and Delivery System |
| Exact Sciences Corporation | $14.72 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $13.98 | 2024 | Interstim |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.